Reduce added sugar
Lowers triglycerides and LDL when less free sugar is eaten. Uric acid and HOMA-IR get no row: isocaloric fructose does not change them defensibly in the opened meta-analyses.
Order of magnitude
Below twenty-five grams of added sugar per day, counted without the sugar from whole fruit.
Te Morenga 2014: higher versus lower sugar raises TG by 0.11 mmol/L and LDL-C by 0.12 mmol/L, including isocaloric trials. The reduction figures are that comparison read backwards (G-S3). Wang 2012: isocaloric fructose does not change uric acid; extreme doses over 200 g/day do, and that is not the product dose. ter Horst 2016: HOMA-IR not significant. ApoB was not pooled. If sugar is replaced by saturated fat, ApoB can rise — that remains an unconfirmed offset without a measured size.
Effects in detail
Each row is a directed edge from our database, with range, latency, evidence grade and the condition under which it applies at all.
| Marker | Effect | Latency | Mode of action | Outcome | Evidence | Condition | Sources |
|---|---|---|---|---|---|---|---|
| Triglycerides | helps. Lowers -9.70 mg/dL confidence interval of the estimate, not the range one person can expect Te Morenga 2014 +0.11 mmol/L TG on higher sugar, read as a fall on lower sugar, at 150 mg/dL. Symmetry is assumed, not shown in reduction trials (G-S3). | 2–2 weeks | chronic | unclear | Evidence grade A | TG at or above 150 mg/dL | |
| Alanine aminotransferase | helps. Lowers -4.94 U/L confidence interval of the estimate, not the range one person can expect In 13 controlled feeding trials in 260 healthy participants, hypercaloric fructose raised ALT by 4.94 U/L (95 % CI 0.03 to 9.85) and raised intrahepatocellular lipid, while isocaloric exchange of fructose for other carbohydrate did nothing. Grade C: few trials, small, four weeks or shorter and of poor quality by the authors' own assessment, and the dose is extreme. | not specified | chronic | unclear | Evidence grade C | applies regardless of the starting value | |
| Apolipoprotein B | helps. Lowers -4.60 mg/dL confidence interval of the estimate, not the range one person can expect Higher sugar intake raised LDL-C by 0.12 mmol/L (95 % CI 0.05 to 0.19) and total cholesterol by 0.16 mmol/L across 39 trials, so a reduction corresponds to about -2 to -7 mg/dL of LDL-C. Row is on LDL-C as the ApoB proxy. Trial proxy: ldl_c. | 2–2 weeks | chronic | unclear | Evidence grade A | applies regardless of the starting value | |
| Diastolic blood pressure | helps. Lowers -5.60 mmHg one bound only: the source gives a subgroup point estimate and no interval In the batch-1 sugar meta-analysis of 39 randomised trials, the blood-pressure effect was greatest in trials lasting at least 8 weeks, where higher sugar intake raised systolic pressure by 6.9 mmHg and diastolic by 5.6 mmHg. Only one bound is entered for each because the source gives a point estimate for the long-trial subgroup and not a confidence interval. | 8–8 weeks | chronic | unclear | Evidence grade B | applies regardless of the starting value | |
| Systolic blood pressure | helps. Lowers -6.90 mmHg one bound only: the source gives a subgroup point estimate and no interval In the batch-1 sugar meta-analysis of 39 randomised trials, the blood-pressure effect was greatest in trials lasting at least 8 weeks, where higher sugar intake raised systolic pressure by 6.9 mmHg and diastolic by 5.6 mmHg. Only one bound is entered for each because the source gives a point estimate for the long-trial subgroup and not a confidence interval. | 8–8 weeks | chronic | unclear | Evidence grade B | applies regardless of the starting value | |
| Uric acid | helps. Lowers -0.52 mg/dL confidence interval of the estimate, not the range one person can expect Across 21 controlled feeding trials, fructose exchanged for other carbohydrates at equal calories left serum urate completely unchanged (+0.56 µmol/L, 95 % CI -6.62 to 7.74). The abstract prints the hypercaloric unit as mmol/L; given the isocaloric unit and the magnitude this is a typographical error for µmol/L, and it has been read as such. | 1–1 weeks | chronic | unclear | Evidence grade B | applies regardless of the starting value |
What this measure costs
Counteracting effects of the same measure.
| Marker | Effect | Latency | Mode of action | Outcome | Evidence | Condition | Sources |
|---|---|---|---|---|---|---|---|
| HbA1c | costs. Raises Direction known, size not established Eighteen controlled feeding trials in 209 people with diabetes found that exchanging fructose isocalorically for other carbohydrate REDUCED glycated blood proteins by a standardised 0.25, which the authors equate to about 0.53 percentage points of HbA1c. A counterintuitive row, kept because it is what the evidence says. | not specified | chronic | unclear | Evidence grade C | applies regardless of the starting value |
Moves without implying progress
Informational or no established effect: the marker moves or was checked, and that is not progress.
| Marker | Effect | Latency | Mode of action | Outcome | Evidence | Condition | Sources |
|---|---|---|---|---|---|---|---|
| HDL cholesterol | moves, and does not count. Lowers -0.80 mg/dL confidence interval of the estimate, not the range one person can expect Higher sugar intake raised HDL-C by 0.02 mmol/L (95 % CI 0.00 to 0.03, p = 0.03), so a reduction lowers it by at most about 1.2 mg/dL. Included as a trade-off row for completeness. | 2–2 weeks | chronic | no | Evidence grade B | applies regardless of the starting value | |
| HOMA-IR | checked, nothing happens. No established effect In 46 comparisons from 29 trials, fructose changed HOMA-IR neither at equal calories (+0.13, 95 % CI -0.07 to 0.34) nor as surplus energy (+0.18, -0.02 to 0.39). A deliberate no-effect row: it shows that a marker in this database cannot detect something the underlying physiology does. | not specified | chronic | unclear | Evidence grade B | applies regardless of the starting value |
Sources
Full details of every study the rows above rely on.
Effect of fructose consumption on insulin sensitivity in nondiabetic subjects: a systematic review and meta-analysis of diet-intervention trials
Ter Horst et al. · American Journal of Clinical Nutrition · 2016 · Review
The effects of fructose intake on serum uric acid vary among controlled dietary trials
Wang DD et al. · Journal of Nutrition · 2012 · Meta-analysis
Dietary sugars and cardiometabolic risk: systematic review and meta-analyses of randomized controlled trials of the effects on blood pressure and lipids
Te Morenga et al. · American Journal of Clinical Nutrition · 2014 · Meta-analysis
Effect of fructose on established lipid targets: a systematic review and meta-analysis of controlled feeding trials
Chiavaroli et al. · Journal of the American Heart Association · 2015 · Meta-analysis
Effect of fructose on markers of non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of controlled feeding trials
Chiu et al. · European Journal of Clinical Nutrition · 2014 · Meta-analysis
Effect of fructose on glycemic control in diabetes: a systematic review and meta-analysis of controlled feeding trials
Cozma et al. · Diabetes Care · 2012 · Meta-analysis
Effect of weight reduction on glycated haemoglobin in weight loss trials in patients with type 2 diabetes
Gummesson et al. · Diabetes, Obesity and Metabolism · 2017 · Review
Effect of dose and duration of reduction in dietary sodium on blood pressure levels: systematic review and meta-analysis of randomised trials
Huang et al. · BMJ · 2020 · Meta-analysis